Division of Breast and Thyroid Gland Surgery, Fukuyama City Hospital, 5-23-1 Zao, Fukuyama, Hiroshima, Japan.
Division of Clinical Research Center, Shizuoka Cancer Center, Shizuoka, Japan.
Sci Rep. 2021 Mar 18;11(1):6328. doi: 10.1038/s41598-021-85948-2.
Although paclitaxel plus bevacizumab (PB) therapy is an effective chemotherapeutic regimen for HER2-negative advanced breast cancer (ABC), predictive markers for its effectiveness remain undefined. We investigated the usefulness of systemic immunity markers associated with lymphocytes as predictive markers for PB therapy in patients with HER2-negative ABC. We retrospectively reviewed data from 114 patients with HER2-negative ABC who underwent PB therapy from November 2011 to December 2019. We calculated the absolute lymphocyte count (ALC), neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and lymphocyte-to-monocyte ratio (LMR) as representative systemic immunity markers. The time to treatment failure (TTF) and overall survival (OS) of the patients with high ALC, low NLR, and high LMR were significantly longer compared with those of the patients with low ALC, high NLR, and low LMR. A multivariable analysis revealed that high ALC, low NLR, and low PLR were independent predictors for TTF and high ALC, low NLR, and high LMR were independent predictors for OS. Systemic immunity markers were significantly associated with longer TTF and OS in patients who underwent PB therapy and may represent predictive markers for PB therapy in patients with HER2-negative ABC.
尽管紫杉醇联合贝伐珠单抗（PB）治疗是 HER2 阴性晚期乳腺癌（ABC）的有效化疗方案，但仍未确定其有效性的预测标志物。我们研究了与淋巴细胞相关的系统免疫标志物在预测 HER2 阴性 ABC 患者 PB 治疗中的作用。我们回顾性分析了 2011 年 11 月至 2019 年 12 月接受 PB 治疗的 114 例 HER2 阴性 ABC 患者的数据。我们计算了绝对淋巴细胞计数（ALC）、中性粒细胞与淋巴细胞比值（NLR）、血小板与淋巴细胞比值（PLR）和淋巴细胞与单核细胞比值（LMR）作为代表性的系统免疫标志物。高 ALC、低 NLR 和高 LMR 患者的治疗失败时间（TTF）和总生存期（OS）明显长于低 ALC、高 NLR 和低 LMR 患者。多变量分析显示，高 ALC、低 NLR 和低 PLR 是 TTF 的独立预测因子，而高 ALC、低 NLR 和高 LMR 是 OS 的独立预测因子。系统免疫标志物与 PB 治疗患者的 TTF 和 OS 明显相关，可能是预测 HER2 阴性 ABC 患者 PB 治疗的标志物。
